Verrica Pharmaceuticals
VRCA
34 hedge funds and large institutions have $10.6M invested in Verrica Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 16 reducing their positions, and 30 closing their positions.
23.45% more ownership
Funds ownership: 2.69% → 26.15% (+23%)
21% less capital invested
Capital invested by funds: $13.4M → $10.6M (-$2.86M)
31% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 16
41% less funds holding
Funds holding: 58 → 34 (-24)
80% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$1.69M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$207K |
| 3 |
Renaissance Technologies
New York
|
+$123K |
| 4 |
Morgan Stanley
New York
|
+$115K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$72.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.5M |
| 2 |
Millennium Management
New York
|
-$113K |
| 3 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$99.1K |
| 4 |
Goldman Sachs
New York
|
-$92.9K |
| 5 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$92.6K |
VRCA Hedge Fund Activity: Q3 2025 in Review
34 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q3 2025, worth a combined $10.6M — down 21% from $13.4M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of VRCA and 6 opened new positions — a net loss of 24 holders — while 16 trimmed existing stakes and 11 added.
The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $1.69M. The largest seller was Armistice Capital, cutting an estimated $1.5M.
- 34 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q3 2025, down from 58 in Q2 2025.
- Funds reported $10.6M of Verrica Pharmaceuticals stock for Q3 2025, down 21% quarter-over-quarter.
- 6 funds opened new Verrica Pharmaceuticals positions in Q3 2025 and 30 closed out, a net change of -24 holders.
- The largest Verrica Pharmaceuticals buyer in Q3 2025 was Boothbay Fund Management, an estimated $1.69M added.
- The largest Verrica Pharmaceuticals seller in Q3 2025 was Armistice Capital, an estimated $1.5M sold.
Based on aggregated 13F filings for Q3 2025.